Management View "We continue to make steady progress in our TakeAim Lymphoma study in primary CNS lymphoma" and said the TakeAi ...

Thank you, and welcome to the Curis First Quarter 2026 Business Update Call. Before we begin, I'd like to encourag ...

Curis (CRIS) is scheduled to announce Q1 earnings results on Tuesday, May 12th, after market close. The consensus EPS Estimate is -$0.29 (+76.8% Y/Y) and the consensus Revenue Estimate is $1.86M (-21.

Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 and FLT3 inhibitor, today announced that the Company ...

Management to host conference call today at 4:30 p.m. ET LEXINGTON, Mass., May 12, 2026 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused ...

A Curis clinical trial under a partial FDA hold for more than a year is now cleared to resume, and the biotech is working with clinical sites to enroll patients whose blood cancers exhibits certain ...

The FDA has freed Curis from a remaining partial clinical hold, lifting the pause on a phase 1/2 leukemia study and giving the green light to launch using the recommended phase 2 dose. In April 2022, ...

The list of biotechs under clinical hold keeps getting longer. Curis is the latest company to join the list, with the FDA slapping a partial hold on a phase 1/2a leukemia study while it gathers ...

Curis (CRIS 1.98%), a small-cap cancer specialist, posted a healthy gain in August. The biotech's shares rose by 16.6% last month, according to data provided by S&P Global Market Intelligence. What ...

What a difference a day makes. Following a serious pop for its stock on Wednesday, given very encouraging news about one of its pipeline drugs, Curis (NASDAQ: CRIS) saw its shares dive by almost 20% ...

Cancer drug specialist Curis (NASDAQ: CRIS) had a Friday to forget. The biotech's share price took a nearly 37% hit after the company reported some disquieting news about a leading pipeline drug.

Management attributes the increased net loss primarily to non-cash fair value adjustments of warrant liabilities from the ...